ICD-10-CM 2027
ICD-10 code for Antithromboplastinogenemia
Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
From the official ICD-10-CM alphabetic index entry “Antithromboplastinogenemia”. Page updated September 29, 2026.
About coding Antithromboplastinogenemia
The ICD-10-CM code for Antithromboplastinogenemia is D68.318 (Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors).
Within D68.31, choose D68.318 (Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors) only when documentation doesn't support a more specific option: acquired hemophilia (D68.311) and Antiphospholipid antibody with hemorrhagic disorder (D68.312).
As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.
In MS-DRG v44.0, it is part of the grouping logic for DRG 813 (Coagulation Disorders, relative weight 1.5257), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
Common questions about Antithromboplastinogenemia ICD-10 codes
What is the ICD-10 code for Antithromboplastinogenemia?
- D68.318 — Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors.
Is D68.318 billable?
- Yes. D68.318 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D68.318 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D68.318 as a principal diagnosis.
Is D68.318 a CC or MCC?
- D68.318 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.